Corcept director David Mahoney disposes of 20,000 shares worth $1.69 million

• Corcept Therapeutics director David L. Mahoney disclosed the sale of 20,000 common shares on June 17, 2026.
• Shares were sold at a weighted average price of USD 84.53, held indirectly through The Black Dog Private Foundation.
• The foundation’s post-transaction stake was 26,147 shares.
• Mahoney also reported 1,237,145 shares held indirectly through the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-275963), on June 18, 2026, and is solely responsible for the information contained therein.